On October 1, United Therapeutics rose 6.63% in regular trading, trading at $577.23/share, with turnover of $456 million, extending gains following a pivotal federal court patent ruling.

The rally was driven by a Delaware federal court ruling that Liquidia Corp's competing drug Yutrepia infringes two claims of United Therapeutics' patent covering inhaled treprostinil for pulmonary hypertension associated with interstitial lung disease (PH-ILD). The ruling could lead to restrictions on Yutrepia's PH-ILD use, potentially reducing competition for United Therapeutics' flagship Tyvaso and Tyvaso DPI products. The company may also benefit from monetary damages related to Liquidia's past infringement, though final remedies remain pending.

The patent victory adds to a series of recent catalysts, including the FDA's acceptance of a supplemental new drug application for Tyvaso nebulized inhalation targeting idiopathic pulmonary fibrosis, with a review expected by late April next year, and the FDA's acceptance of a new drug application for ralinepag in pulmonary arterial hypertension, with a target approval date of June next year.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)